Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT04915755

PHASE3

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast cancer (Independent of hormone receptor \[HR\] status, including HR positive \[+\] and TNBC) or tumor BRCA wild type (tBRCAwt) TNBC with molecular disease based on the presence of circulating tumor Deoxyribonucleic acid (ctDNA) following surgery or completion of adjuvant therapy.

Official title: A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2021-06-28

Completion Date

2025-12-31

Last Updated

2025-07-16

Healthy Volunteers

Conditions

Neoplasms, Breast

Interventions

DRUG

Niraparib

Niraparib will be administered.

DRUG

Placebo

Matching placebo will be administered

Inclusion Criteria: * Stage I to III breast cancer with surgical resection of the primary tumor that is confirmed to be either: TNBC, irrespective of BRCA status or HR+/HER2- breast cancer with a known and documented deleterious or suspected deleterious tBRCA mutation. * Estrogen receptor (ER) and/or progesterone receptor (PgR) negativity is defined as immunohistochemistry (IHC) nuclear staining less than (\<) 1 percentage (%), or by Allred scoring system where TNBC is defined to be 0 out of 8 or 2 out of 8, or staining in \<1 % of cancer cells. * Completed prior standard therapy for curative intent. * Participants with HR+ breast cancer must be on a stable regimen of endocrine therapy. * Detectable ctDNA as measured by central testing. * An archival tumor tissue specimen of the primary tumor sufficient in quality and quantity for ctDNA assay design and tBRCA and Homologous recombination deficiency (HRD) testing is required. * An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria: * Prior treatment with a Poly Adenosine-diphosphate Ribose Polymerase (PARP) inhibitor. * Current treatment with a Cyclin-dependent kinase (CDK)4/6 inhibitor or endocrine therapy other than anastrozole, letrozole, exemestane, and tamoxifen with or without ovarian suppression. * Participants have any sign of metastasis or local recurrence after comprehensive assessment conducted per protocol. * Participants have shown no definitive response to preoperative chemotherapy by pathologic, radiographic or clinical evaluation, in cases where preoperative chemotherapy was administered. * Participants have inadequately treated or controlled hypertension. * Participants have received live vaccine within 30 days of planned start of study randomization. * Participants have a second primary malignancy. * Exceptions are the following: (a) Adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, Ductal carcinoma in situ (DCIS) of the breast, Stage I Grade 1 endometrial carcinoma. (b) Other solid tumors and lymphomas (without bone marrow involvement) diagnosed \>=5 years prior to randomization and treated with no evidence of disease recurrence and for whom no more than 1 line of chemotherapy was applied. * Participant is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and/or for up to 180 days after the last dose of study treatment (except France). * Participant is immunocompromised. Participants with splenectomy are allowed. Participants with known human immunodeficiency virus (HIV) are allowed if they meet protocol-defined criteria. * Participants have a known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

Locations (198)

GSK Investigational Site

Burbank, California, United States

GSK Investigational Site

Duarte, California, United States

GSK Investigational Site

Palo Alto, California, United States

GSK Investigational Site

San Francisco, California, United States

GSK Investigational Site

Aurora, Colorado, United States

GSK Investigational Site

Highlands Ranch, Colorado, United States

GSK Investigational Site

Chicago, Illinois, United States

GSK Investigational Site

Skokie, Illinois, United States

GSK Investigational Site

Ann Arbor, Michigan, United States

GSK Investigational Site

Albuquerque, New Mexico, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

Fargo, North Dakota, United States

GSK Investigational Site

Philadelphia, Pennsylvania, United States

GSK Investigational Site

Pittsburgh, Pennsylvania, United States

GSK Investigational Site

Sioux Falls, South Dakota, United States

GSK Investigational Site

Austin, Texas, United States

GSK Investigational Site

Dallas, Texas, United States

GSK Investigational Site

Dallas, Texas, United States

GSK Investigational Site

Fort Worth, Texas, United States

GSK Investigational Site

Houston, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

Tyler, Texas, United States

GSK Investigational Site

Norfolk, Virginia, United States

GSK Investigational Site

Everett, Washington, United States

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Capital Federal, Argentina

GSK Investigational Site

Cipoletti Rio Negro, Argentina

GSK Investigational Site

Ciudad Autonoma Buenos Aires, Argentina

GSK Investigational Site

Ciudad AutOnoma de Buenos Aire, Argentina

GSK Investigational Site

Ciudad Autonoma de Buenos Aire, Argentina

GSK Investigational Site

Ciudad de Buenos Aires, Argentina

GSK Investigational Site

Entre Ríos, Argentina

GSK Investigational Site

Camperdown, New South Wales, Australia

GSK Investigational Site

Macquarie Park, New South Wales, Australia

GSK Investigational Site

North Sydney, New South Wales, Australia

GSK Investigational Site

Feldkirch, Austria

GSK Investigational Site

Innsbruck, Austria

GSK Investigational Site

Steyr, Austria

GSK Investigational Site

Vienna, Austria

GSK Investigational Site

Brussels, Belgium

GSK Investigational Site

Brussels, Belgium

GSK Investigational Site

Charleroi, Belgium

GSK Investigational Site

Ghent, Belgium

GSK Investigational Site

Leuven, Belgium

GSK Investigational Site

Belo Horizonte, Brazil

GSK Investigational Site

Florianópolis, Brazil

GSK Investigational Site

Porto Alegre, Brazil

GSK Investigational Site

Porto Alegre, Brazil

GSK Investigational Site

Rio de Janeiro, Brazil

GSK Investigational Site

Rio Grande, Brazil

GSK Investigational Site

Salvador, Brazil

GSK Investigational Site

São Paulo, Brazil

GSK Investigational Site

São Paulo, Brazil

GSK Investigational Site

Vitória, Brazil

GSK Investigational Site

Calgary, Alberta, Canada

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Montreal, Quebec, Canada

GSK Investigational Site

Québec, Quebec, Canada

GSK Investigational Site

Santiago, Chile

GSK Investigational Site

Santiago, Chile

GSK Investigational Site

Temuco, Chile

GSK Investigational Site

Helsinki, Finland

GSK Investigational Site

Helsinki, Finland

GSK Investigational Site

Turku, Finland

GSK Investigational Site

Avignon, France

GSK Investigational Site

Bordeaux, France

GSK Investigational Site

Caen, France

GSK Investigational Site

Dijon, France

GSK Investigational Site

Marseille, France

GSK Investigational Site

Montpellier, France

GSK Investigational Site

Pierre-Bénite, France

GSK Investigational Site

Rouen, France

GSK Investigational Site

Saint-Cloud, France

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Cologne, Germany

GSK Investigational Site

Erlangen, Germany

GSK Investigational Site

Essen, Germany

GSK Investigational Site

Mannheim, Germany

GSK Investigational Site

München, Germany

GSK Investigational Site

Ulm, Germany

GSK Investigational Site

Debrecen, Hungary

GSK Investigational Site

Dublin, Ireland

GSK Investigational Site

Dublin, Ireland

GSK Investigational Site

Beersheba, Israel

GSK Investigational Site

Haifa, Israel

GSK Investigational Site

Jerusalem, Israel

GSK Investigational Site

Jerusalem, Israel

GSK Investigational Site

Petah Tikva, Israel

GSK Investigational Site

Rehovot, Israel

GSK Investigational Site

Tel Aviv, Israel

GSK Investigational Site

Ancona, Italy

GSK Investigational Site

Ancona, Italy

GSK Investigational Site

Bologna, Italy

GSK Investigational Site

Brindisi, Italy

GSK Investigational Site

Candiolo to, Italy

GSK Investigational Site

Catania, Italy

GSK Investigational Site

Genova, Italy

And 98 more locations on ClinicalTrials.gov

Clinical Research Directory

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (198)